UNSPSC 51191554: Isosorbide dinitrate

This classification denotes a vasodilating agent with the molecular formula C6H8N2O8, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier IA7306519N, chemically known as 1,4:3,6-dianhydrosorbitol 2, 5-dinitrate but generally known as isosorbide dinitrate, which bears US NIH Compound Identifier 3780. European Medicines Agency schedules Isosorbide dinitrate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08335MIG.

UNSPSC 51191554 Isosorbide dinitrate is a Commodity code that nominally addresses a specific cardiac medication, but recent state and local solicitations tagged under this code show minimal activity directly aligned with the pharmaceutical's intended scope. The two recent opportunities in the record reflect divergent procurement activity: a City of Meriden IFB for sodium bisulfite chemical supply for water pollution control operations (due July 29, 2026), and a Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) RFP for generic multi-source pharmaceuticals and over-the-counter products (due March 26, 2026). The sodium bisulfite bid is plainly unrelated to isosorbide dinitrate; the MMCAP RFP addresses pharmaceuticals broadly but does not isolate isosorbide dinitrate as a line item. This code shows little concrete recent activity specifically targeting the product named in its taxonomy definition.

The geographic spread evident in the source is limited to Connecticut (City of Meriden) and Minnesota with Oregon participation (MMCAP cooperative). Issuing bodies include a municipal water utility and a multi-state cooperative purchasing organization administered by a state procurement office. Without additional recent solicitations tied explicitly to isosorbide dinitrate supply or demand signals, this code does not present a clear active procurement category for business development focus. Vendors evaluating pursuit should verify whether state and local health agencies, institutional pharmacies, or medical facilities are actively soliciting this medication through separate channels or cooperative vehicles not reflected in the current opportunity record.